PTGX

PROTAGONIST THERAPEUTICS INC

PTGX·74366E102·US·Common Stock·Healthcare - Biotechnology-13D/G

PTGX (PROTAGONIST THERAPEUTICS INC) is held by 169 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($1.3B), FARALLON CAPITAL MANAGEMENT, L.L.C. ($778.2M), RTW INVESTMENTS, LP ($620.4M). Net institutional sentiment: Mixed.

169
Holders
(16 Elite)
$7.7B
Total Value
63% (172)
Consensus
108 buying - 64 selling
13F: Insider & Congress: Updated regularly
PTGX

Smart Money Verdict

View all
Loading verdict
Held by 169 funds
16 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Jun 11, 2026 · Activists Aug 13, 2026 · Congress none

ActivistFarallon Capital Management, L.L.C.Farallon Capital Management, L.L.C.10.0%Aug 13, 2026
ActivistSTATE STREET CORPORATIONSTATE STREET CORPORATION5.2%Aug 7, 2026
InsiderWDWaddill William D.Sell $969KJun 10, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
10.3M(+5.4%)$1.3B0.0%+223.47%
34
Unchanged
6.3M$778.2M3.6%+566.37%
0
Increased
5.1M(+0.0%)$620.4M5.3%+491.61%
61
Increased
3.6M(+4.3%)$444.9M0.0%+55.90%
33
Decreased
3.4M(-5.1%)$418.8M0.1%+109.89%
0
Decreased
3.4M(-34.4%)$416.7M0.1%+87.82%
0
Increased
3.3M(+6.6%)$407.2M0.0%+251.22%
33
Increased
2.9M(+1.7%)$349.8M0.0%+57.19%
32
Increased
2.3M(+8.1%)$286.9M0.0%+93.26%
33
Increased
1.7M(+4.3%)$213.5M0.0%+292.96%
32
Unchanged
1.4M$173.3M0.5%+201.03%
0
Increased
1.3M(+2.2%)$162.4M0.0%+118.13%
31
Increased
1.2M(+7.4%)$141.2M0.1%+56.37%
33
Decreased
905,992(-11.0%)$111.1M0.0%+153.95%
0
Increased
889,298(+49.9%)$109M0.3%+43.17%
50
Increased
882,738(+6.5%)$108.2M0.8%+54.87%
45
Increased
812,852(+4.3%)$99.6M0.0%+164.08%
31
Increased
731,053(+1.4%)$89.6M0.5%+167.94%
43
Increased
725,335(+16.6%)$88.9M0.1%+55.13%
35
Increased
672,186(+1.5%)$82.4M0.0%+173.41%
30

Showing 1-20 of 184

1 / 10
PTGXPTGXPROTAGONIST THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used